Chronix presents head/neck cancer data at ASCO

Related Posts

15Jan

University of Minnesota Twin Cities and Windgap Medical receive $3.2 million NIH grant to develop cyanide antidote autoinjector

The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of... read more
20May

Michael Bayer: ‘CFOs Are Storytellers’

Michael Bayer, CFO of Wasabi Technologies, asked this rhetorical question in response to CFO’s inquiry about the business outlook for... read more
26Jul

Regroup Mass Notification at the Biggest Event in Brazil for Emergency and Safety Professionals

Regroup Mass Notification, the industry-leading provider of emergency and day-to-day communication solutions, announced that it will be attending the 2017... read more
16Mar

Myomo, a Robotic Arm Brace Maker, Aims to Raise $15M in “Mini-IPO”

Myomo, a privately held medical device company spun out of MIT, has launched an unusually structured public offering of stock... read more
07Feb

Regroup Mass Notification Launches New Partnership With Code Blue

Regroup Mass Notification, an industry leading provider of mass communication solutions, today announced a strategic alliance with Code Blue Corporation,... read more
13Feb

GE 242: How Founder Bettina Hein Has Grown Video Advertising Platform Pixability 100% per Year for the Last 5 Years

Hey everyone, in today’s episode I share the mic with Bettina Hein, founder and CEO of Pixability, a video advertising... read more
31Dec

Corbus Concludes Phase II study of Cystic Fibrosis Candidate

Corbus Pharmaceuticals Holdings, Inc. CRBP , recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab),... read more
16Oct

Salesforce-backed Bay Area entrepreneur strikes big deal to ‘crush’ student loan debt

Laurel Taylor, founder and CEO of FutureFuel.io, knows firsthand the opportunities and struggles that come with taking on large student... read more
04Mar

CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease

All mentions of NLY01 have been corrected -- Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders,... read more
17Sep

Regroup Mass Notification Wins Security Today’s New Product of The Year Award

Regroup Mass Notification, an industry-leading provider of emergency and day-to-day mass notification solutions, today announced that Security Today has awarded... read more